Inventor · disambiguated record
Gokhan S. Hotamisligil
Also filed as: HOTAMISLIGIL GOEKHAN · HOTAMISLIGIL GOEKHAN S · HOTAMISLIGIL GOKHAN · HOTAMISLIGIL GOKHAN S
17 granted patents·22 pending applications·375 citations·filing 1994–2025
93Inventor score
Files withHARVARD COLLEGE18CRESCENTA BIOSCIENCES4HOTAMISLIGIL GOKHAN S3DANA FARBER CANCER INST INC2HARVARD UNIVERSITY PRESIDENT A2
Top patents by PatentIndex Score
39 records- 0195US6015558ATreatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-α functionDANA FARBER CANCER INST INC·Filed 1998·Granted Jan 18, 2000·134 cites·5 claims
- 0295US5730975ATreatment of insulin resistance in obesity linked type II diabetes using antagonist to TNF-alpha functionDANA FARBER CANCER INST INC·Filed 1994·Granted Mar 24, 1998·148 cites·13 claims
- 0391US7232897B2Compositions and methods for modulating NH2-terminal Jun Kinase activityHARVARD UNIVERSITY PRESIDENT A·Filed 2002·Granted Jun 19, 2007·65 cites·10 claims
- 0488US11685774B2Method of reducing blood glucose levels and inhibiting secreted aP2HARVARD COLLEGE·Filed 2020·Granted Jun 27, 2023·1 cites·6 claims
- 0588US11014979B2Anti-AP2 antibodies and antigen binding agents to treat metabolic disordersHARVARD COLLEGE·Filed 2018·Granted May 25, 2021·4 cites·35 claims
- 0687US12454569B2Method of reducing glucose intolerance or insulin resistance in a patient in need thereofHARVARD COLLEGE·Filed 2023·Granted Oct 28, 2025·0 cites·14 claims
- 0785US12247068B2Anti-AP2 antibodies and antigen binding agents to treat metabolic disordersHARVARD COLLEGE·Filed 2021·Granted Mar 11, 2025·1 cites·19 claims
- 0882US10160798B2Anti-aP2 antibodies and antigen binding agents to treat metabolic disordersHARVARD COLLEGE·Filed 2016·Granted Dec 25, 2018·4 cites·48 claims
- 0981US7358254B2Method for treating atherosclerosis employing an aP2 inhibitor and combinationBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Apr 15, 2008·14 cites·2 claims
- 1078US10882901B2Methods of treating diabetes by an adipocyte protein 2 specific antibodyHARVARD COLLEGE·Filed 2017·Granted Jan 5, 2021·1 cites·5 claims
- 1175US9879078B2Method of treating lipodystrophy in HIV-infected humansHARVARD COLLEGE·Filed 2016·Granted Jan 30, 2018·1 cites·4 claims
- 1274US11345748B2Method of treating idiopathic pulmonary fibrosis and kidney fibrosisHARVARD COLLEGE·Filed 2019·Granted May 31, 2022·1 cites·5 claims
- 1373US2025346654A1Anti-ap2 antibodies and antigen binding agents to treat metabolic disordersHARVARD COLLEGE·Filed 2025·Application pending·0 cites
- 1471US2025346646A1Compounds useful to treat metabolic disordersHARVARD COLLEGE·Filed 2025·Application pending·0 cites
- 1564US2022411490A1Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disordersHARVARD COLLEGE·Filed 2022·Application pending·0 cites
- 1663US2009076033A1Method for treating atherosclerosis employing an aP2 inhibitor and combinationROBL JEFFREY A·Filed 2008·Application pending·0 cites
- 1762US7056662B2Method of diagnosing a risk of developing insulin resistanceHARVARD COLLEGE·Filed 2001·Granted Jun 6, 2006·1 cites·6 claims
- 1862US2010022495A1Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosisHARVARD COLLEGE·Filed 2006·Application pending·0 cites
- 1962US2021171599A1Compounds useful to treat metabolic disordersHARVARD COLLEGE·Filed 2020·Application pending·0 cites
- 2061US2007207137A1Inhibition of Jun KinaseHARVARD UNIVERSITY PRESIDENT A·Filed 2007·Application pending·0 cites
- 2159US2019135888A1Compounds useful to treat metabolic disordersHARVARD COLLEGE·Filed 2018·Application pending·0 cites
- 2257US2014011761A1Modulating Endoplasmic Reticulum Stress in the Treatment of Tuberous SclerosisHARVARD COLLEGE·Filed 2012·Application pending·0 cites
- 2353US2016008309A1Use of trans-palmitoleate in identifying and treating metabolic diseaseHARVARD COLLEGE·Filed 2014·Application pending·0 cites
- 2452US9987243B2Use of trans-palmitoleate in identifying and treating metabolic diseaseTUFTS COLLEGE·Filed 2016·Granted Jun 5, 2018·0 cites·3 claims
- 2552US2012134998A1Secreted ap2 and methods of inhibiting sameHOTAMISLIGIL GOKHAN S·Filed 2010·Application pending·0 cites
- 2651US2014228422A1Targets for treatment of er stressHOTAMISLIGIL GÖKHAN S·Filed 2013·Application pending·0 cites
- 2751US2010075894A1Reducing er stress in the treatment of obesity and diabetesUNIV HARVARD·Filed 2009·Application pending·0 cites
- 2850US2023210837A1Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseasesCRESCENTA BIOSCIENCES·Filed 2021·Application pending·0 cites
- 2950US2006073213A1Reducing ER stress in the treatment of obesity and diabetesHOTAMISLIGIL GOKHAN S·Filed 2005·Application pending·0 cites
- 3050US2022313681A1Novel cell metabolism modulating compounds and uses thereof for the treatment of viral diseasesCRESCENTA BIOSCIENCES·Filed 2022·Application pending·0 cites
- 3150US2009012020A1Inhibiting formation of atherosclerotic lesionsLEE MU-EN·Filed 2007·Application pending·0 cites
- 3249US12138243B2Antiviral use of FABP4 modulating compoundsCRESCENTA BIOSCIENCES·Filed 2021·Granted Nov 12, 2024·0 cites·50 claims
- 3349US2023203142A1Treatment of metabolic disorders through the targeting of a novel circulating hormone complexTHE PRESIDENT AND FELLOWS OF HARVARD COLLEGE·Filed 2022·Application pending·0 cites
- 3447US2023255933A1Antiviral use of fabp4 modulating compoundsCRESCENTA BIOSCIENCES·Filed 2021·Application pending·0 cites
- 3546US9239334B2Fatty acid C16: 1N7-palmitoleate a lipokine and biomarker for metabolic statusCAO HAIMING·Filed 2009·Granted Jan 19, 2016·0 cites·1 claims
- 3645US8889739B2Use of trans-palmitoleate in identifying and treating metabolic diseaseMOZAFFARIAN DARIUSH·Filed 2011·Granted Nov 18, 2014·0 cites·1 claims
- 3745US2009312297A1Methods for treating hypercholesterolemia and atherosclerosisHARVARD COLLEGE·Filed 2007·Application pending·0 cites
- 3843US2006063187A1Modulation of XBP-1 activity for treatment of metabolic disordersHOTAMISLIGIL GOKHAN S·Filed 2005·Application pending·0 cites
- 3943US2001046966A1Inhibition of adipogenesisFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →